Protocol summary

Study aim
Comparison of The Efficacy of Ketamine and Intravenous Dexmedetomidine in Preventing Agitation in Children with Cancer Before Biopsy and Bone Marrow Aspiration
Design
Clinical trial on two parallel intervention groups Bilaterally blind with block randomization method Phase 3 on 72 patients
Settings and conduct
This study was a double-blind randomized clinical trial with parallel groups in which children aged 2 to 15 years who were candidates for bone marrow biopsy and aspiration procedures were divided into two identical groups: Dexmedetomidine and Ketamine and They are then compared for agitation and vital signs.
Participants/Inclusion and exclusion criteria
Inclusion criteria: 1- All children 2 to 15 years old who are candidates for biopsy and bone marrow aspiration or intrathecal chemotherapy. 2- Obtaining informed consent from the patient (parents) Conditions of non-entry: 1- Existence of contraindication of lumbar puncture 2- History of cardiopulmonary and renal disease 3- Existence of anatomical disorders in the patient's neck and spine
Intervention groups
Children eligible for the study are randomly divided into 2 intervention groups who receive 1-ketamine and 2-dexmedetomidine before biopsy and bone marrow aspiration.
Main outcome variables
4-point sedation scale measured at 5, 10, 20, 30 minutes after drug injection. Respiratory rate per minute, measured at 5, 10, 20, 30 minutes after drug injection. Blood pressure is measured at 5, 10, 20, 30 minutes after drug injection. Oxygen saturation is measured at 5, 10, 20, 30 minutes after drug injection. Heart rate per minute measured at 5, 10, 20, 30 minutes after drug injection. .

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20240416061503N1
Registration date: 2024-04-19, 1403/01/31
Registration timing: prospective

Last update: 2024-04-19, 1403/01/31
Update count: 0
Registration date
2024-04-19, 1403/01/31
Registrant information
Name
Shabnam ‌Asadi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 26 3442 6358
Email address
shabnam.asadi97@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-04-29, 1403/02/10
Expected recruitment end date
2024-05-21, 1403/03/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
A Comparative Study of The Efficacy of Ketamine and Intravenous Dexmedetomidine in Preventing Agitation in Children with Cancer Before Biopsy and Bone Marrow Aspiration
Public title
A Comparative Study of The Efficacy of Ketamine and Intravenous Dexmedetomidine in Preventing Agitation in Children with Cancer Before Biopsy and Bone Marrow Aspiration
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
1. All children aged 2 to 15 who are candidates for bone marrow biopsy and aspiration or intrathecal chemotherapy. 2.Obtaining informed consent from the patient (parents) 3. Absence of anatomical disorders in the patient's neck and spine 4. No history of heart, lung and kidney disease 5. No contraindications to LP
Exclusion criteria:
Age
From 2 years old to 15 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Investigator
Sample size
Target sample size: 72
Randomization (investigator's opinion)
Randomized
Randomization description
Participants are assigned to two intervention and control groups, respectively, based on the randomization sequence that will be generated beforehand. This sequence is unpredictable and its arrangement is completely random. Block randomization method with 8 blocks will be used to allocate samples. Thus, using block numerical random number generation software, a randomization sequence proportional to the sample size required for the two groups will be generated. Initially, all cases in which the two letters A and B can be arranged in blocks of 8 are produced. A block is then randomly selected from the blocks and the layout pattern in that block will be used to assign participants. This block will then be placed in the main container and another block will be selected again. All this will be done with software called Sealed Envelope. With this method, concealment will also be observed. The concept of concealment is to unpredictably assign individuals to groups. In fact, the researcher will not be able to predict which group the next person will be in.
Blinding (investigator's opinion)
Double blinded
Blinding description
Vials of the same volume are drawn into the same syringes, and the patient's participant and clinical caregiver (nurse) are unaware of its contents.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Research Ethics Committee of Arak University of Medical Sciences
Street address
Research Assistant, Arak University of Medical Sciences, Basij Square, Sardasht, Arak, Iran
City
Arak
Province
Markazi
Postal code
3848176341
Approval date
2023-03-14, 1401/12/23
Ethics committee reference number
IR.ARAKMU.REC.1401.316

Health conditions studied

1

Description of health condition studied
Agitation before aspiration and bone marrow biopsy
ICD-10 code
R45.1
ICD-10 code description
Restlessness and agitation

Primary outcomes

1

Description
4-point scale of sedation
Timepoint
which is measured in 5, 10, 20, 30 minutes after drug injection
Method of measurement
4-point degree of sedation is: restlessness: 4 awake: 3 drowsy: 2 asleep: 1. (In this scale, grades 1 and 2 are desirable.) This scale is measured based on the doctor's judgment during the examination.

Secondary outcomes

1

Description
Respiratory Rate
Timepoint
It is measured in 5, 10, 20, 30 minutes after drug injection
Method of measurement
Counting

2

Description
Blood pressure
Timepoint
It is measured in 5, 10, 20, 30 minutes after drug injection
Method of measurement
Pressure cuff

3

Description
Oxygen saturation
Timepoint
It is measured in 5, 10, 20, 30 minutes after drug injection
Method of measurement
Pulse oximetry

4

Description
Heart Rate
Timepoint
It is measured in 5, 10, 20, 30 minutes after drug injection
Method of measurement
Counting

Intervention groups

1

Description
Intervention group: The Dexmedetomidine group received 2 µg/kg intravenously within 10 minutes before the biopsy procedure and bone marrow aspiration or intrathecal chemotherapy. The vials of drugs with the same volume are drawn into the same syringes and the team members, nurses, patients and anesthesiologists are not aware of the division of groups. And an anesthesiologist who is not involved in the study prepares the drugs in the syringe and codes according to the randomization code.
Category
Treatment - Drugs

2

Description
Control group: The Ketamine group received 5 to 10 micrograms per kilogram intravenously before the biopsy procedure and bone marrow aspiration or intrathecal chemotherapy. This group is considered as the control group. The vials of drugs with the same volume are drawn into the same syringes and the team members, nurses, patients and anesthesiologists are not aware of the division of groups. And an anesthesiologist who is not involved in the study prepares the drugs in the syringe and codes according to the randomization code.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Amirkabir Hospital of Arak
Full name of responsible person
Atbin Latifi
Street address
Amirkabir Hospital of Arak, Shahid Shiroudi St., Parstar Square
City
Arak
Province
Markazi
Postal code
3819691187
Phone
+98 86 3313 4715
Email
latifiatbin@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Davoud Hekmatpou
Street address
Research Assistant, Arak University of Medical Sciences, Basij Square, Sardasht, Arak, Iran
City
Arak
Province
Markazi
Postal code
3848176341
Phone
+98 86 3417 3532
Email
research@arakmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Arak University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Atbin Latifi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Amirkabir Hospital of Arak, Shahid Shiroudi St., Parstar Square
City
Arak
Province
Markazi
Postal code
3819691187
Phone
+98 86 3313 4715
Email
it@arakmu.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Atbin Latifi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Amirkabir Hospital of Arak, Shahid Shiroudi St., Parstar Square
City
Arak
Province
Markazi
Postal code
3819691187
Phone
+98 86 3313 4715
Email
it@arakmu.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Shabnam Asadi
Position
Medical Intern
Latest degree
A Level or less
Other areas of specialty/work
General Practitioner
Street address
No 15, East 10th street, Enghelab Blvd.
City
Karaj
Province
Alborz
Postal code
3148863538
Phone
+98 26 3442 6358
Email
shabnam.asadi97@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
After the publication of the article, confidential information such as patient and hospital details, etc. will be deleted and other information will be provided to researchers.
When the data will become available and for how long
After publishing the article
To whom data/document is available
Medical specialists
Under which criteria data/document could be used
Medical professionals can access the data for research purposes.
From where data/document is obtainable
Email the corresponding author
What processes are involved for a request to access data/document
Official and academic email to the corresponding author
Comments
Loading...